bluebird bio Adds Biotech Industry Veterans to Management Team and Board

CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, a leader in the development of innovative gene therapies for severe genetic disorders, today announced the appointment of Jeffrey T. Walsh to the position of chief operating officer and Daniel S. Lynch to the company’s board of directors.

Back to news